We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.
Filters applied:
Medicine & public health

Search Results

Showing 1-20 of 555 results

  1. Inotuzumab Ozogamicin: First Pediatric Approval

    Inotuzumab ozogamicin (BESPONSA™) is a CD22-targeted monoclonal antibody drug conjugate (ADC) developed by Pfizer for the treatment of CD22-postive...

    Sohita Dhillon in Pediatric Drugs
    Article 23 May 2024

  2. Population Pharmacokinetics of Inotuzumab Ozogamicin in Pediatric Relapsed/Refractory B-Cell Precursor Acute Lymphoblastic Leukemia: Results of Study ITCC-059

    Background and Objective

    Inotuzumab ozogamicin is an antibody-drug conjugate approved for treating relapsed/refractory B-cell precursor acute...

    Jen-Hao Wu, Edoardo Pennesi, ... Alwin D. R. Huitema in Clinical Pharmacokinetics
    Article Open access 22 June 2024

  3. Inotuzumab-ozogamicin

    in Reactions Weekly
    Article 20 April 2024

  4. Inotuzumab-ozogamicin

    in Reactions Weekly
    Article 30 March 2024

  5. Inotuzumab-ozogamicin

    in Reactions Weekly
    Article 09 March 2024

  6. Inotuzumab ozogamicin for the treatment of adult acute lymphoblastic leukemia: past progress, current research and future directions

    Inotuzumab ozogamicin (INO) is an anti-CD22 antibody-drug conjugate that was first evaluated in B-cell lymphomas but was subsequently shown to be...

    Nicholas J. Short, Elias Jabbour, ... Hagop Kantarjian in Journal of Hematology & Oncology
    Article Open access 11 May 2024

  8. Inotuzumab-ozogamicin

    in Reactions Weekly
    Article 30 September 2023

  9. Inotuzumab-ozogamicin

    in Reactions Weekly
    Article 26 August 2023

  16. Inotuzumab-ozogamicin

    in Reactions Weekly
    Article 07 January 2023

  17. Results of salvage therapy with mini-hyper-CVD and inotuzumab ozogamicin with or without blinatumomab in pre-B acute lymphoblastic leukemia

    Background

    Historically, adults with relapsed-refractory acute lymphoblastic leukemia (ALL) experienced poor outcomes with intensive chemotherapy....

    Hagop Kantarjian, Fadi G. Haddad, ... Elias Jabbour in Journal of Hematology & Oncology
    Article Open access 02 May 2023

  18. Inotuzumab-ozogamicin

    in Reactions Weekly
    Article 29 October 2022
Did you find what you were looking for? Share feedback.